Maggie Tibbitt

Articles

KEYNOTE-826 data in cervical cancer and next steps for research

October 05, 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the practice-changing data from KEYNOTE-826 examining pembrolizumab plus chemotherapy with or without bevacizumab and next steps for research in recurrent or metastatic cervical cancer.